Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy for mucosal melanoma.

Literature DB >> 31576325

Immunotherapy for mucosal melanoma.

Sarah Yentz¹, Christopher D Lao¹.

Abstract

Entities: Disease

Year: 2019 PMID： 31576325 PMCID： PMC6685869 DOI： 10.21037/atm.2019.05.62

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

17 in total

Review 1. Mucosal melanoma: pathogenesis, clinical behavior, and management.

Authors: Michael A Postow; Omid Hamid; Richard D Carvajal
Journal: Curr Oncol Rep Date: 2012-10 Impact factor: 5.075

2. Incidence of noncutaneous melanomas in the U.S.

Authors: Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen
Journal: Cancer Date: 2005-03-01 Impact factor: 6.860

3. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Authors: Alexander N Shoushtari; Mark J Bluth; Debra A Goldman; Christiana Bitas; Robert A Lefkowitz; Michael A Postow; Rodrigo R Munhoz; Gauri Buchar; Robert H Hester; Jacqueline A Romero; Laura J Fitzpatrick; Martin R Weiser; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman; Richard D Carvajal
Journal: Melanoma Res Date: 2017-02 Impact factor: 3.599

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

5. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Authors: Bin Lian; Lu Si; Chuanliang Cui; Zhihong Chi; Xinan Sheng; Lili Mao; Siming Li; Yan Kong; Bixia Tang; Jun Guo
Journal: Clin Cancer Res Date: 2013-07-05 Impact factor: 12.531

6. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors: Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal: J Clin Oncol Date: 2016-11-07 Impact factor: 44.544

7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245

8. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

Authors: Zhihong Chi; Siming Li; Xinan Sheng; Lu Si; Chuanliang Cui; Mei Han; Jun Guo
Journal: BMC Cancer Date: 2011-02-25 Impact factor: 4.430

9. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors: Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal: Genome Med Date: 2017-04-19 Impact factor: 11.117

10. Mucosal melanomas in the racially diverse population of California.

Authors: Lisa Altieri; Michael K Wong; David H Peng; Myles Cockburn
Journal: J Am Acad Dermatol Date: 2016-10-11 Impact factor: 15.487

9 in total

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Authors: Narjess Ayati; Ramin Sadeghi; Zahra Kiamanesh; Sze Ting Lee; S Rasoul Zakavi; Andrew M Scott
Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-29 Impact factor: 9.236

2. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.

Authors: So-Woon Kim; Young Il Kim; Bilal Mustafa; Mi-Ju Kim; Gowun Jeong; Sung-Min Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seung-Mo Hong; In Ja Park
Journal: Mod Pathol Date: 2020-07-24 Impact factor: 7.842

3. Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion.

Authors: Laurence Pincet; Karma Lambercy; Philippe Pasche; Martin Broome; Sofiya Latifyan; Antoine Reinhard
Journal: Front Surg Date: 2021-01-20

4. Complete Response After Stereotactic Body Radiation Therapy With Concurrent Immunotherapy for Vaginal Melanoma.

Authors: Caitlin A Schonewolf; Elizabeth M Jaworski; Steven G Allen; Karen McLean; Christopher D Lao; Lynn M Schuchter; Janos Tanyi; Neil K Taunk
Journal: Adv Radiat Oncol Date: 2021-10-28

Review 5. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.

Authors: Devayani Machiraju; Sarah Schäfer; Jessica C Hassel
Journal: Life (Basel) Date: 2021-11-30

Review 6. Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma.

Authors: Antonio Giuliano
Journal: Biology (Basel) Date: 2021-12-31

Immunotherapy for mucosal melanoma.

Review 1. Mucosal melanoma: pathogenesis, clinical behavior, and management.

2. Incidence of noncutaneous melanomas in the U.S.

3. Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

5. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

6. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

7. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

8. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

9. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

10. Mucosal melanomas in the racially diverse population of California.

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

2. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.

3. Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion.

4. Complete Response After Stereotactic Body Radiation Therapy With Concurrent Immunotherapy for Vaginal Melanoma.

Review 5. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.

Review 6. Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma.

7. MicroRNA-153-3p sensitizes melanoma cells to dacarbazine by suppressing ATG5-mediated autophagy and apoptosis.

8. Mutational profiling of melanomas in patients from the southeast coast of China.

9. Sinonasal mucosal melanoma: a 10-year experience of 36 cases in China.

Review 1. Mucosal melanoma: pathogenesis, clinical behavior, and management.

Review 1. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Review 5. Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.

Review 6. Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma.

Review 1. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.